Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

Journal of Clinical Investigation

Volumn 116, Issue 7, 2006, Pages 1784-1792

  Kadowaki, Takashi ^a,b   Yamauchi, Toshimasa ^a   Kubota, Naoto ^a,b   Hara, Kazuo ^a,b   Ueki, Kohjiro ^a   Tobe, Kazuyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; GLITAZONE DERIVATIVE; INSULIN; PIOGLITAZONE; ROSIGLITAZONE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADIPOSE TISSUE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE;

EID: 33745834319     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29126     Document Type: Review

References (118)

1. Flier, J.S. 2004. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 116:337-350.
2. Friedman, J.M. 2000. Obesity in the new millennium. Nature. 404:632-634.
3. Reaven, G.M. 1998. Role of insulin resistance in human disease. Diabetes. 37:1595-1607.
4. Kaplan, N.M. 1989. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149:1514-1520.
5. Matsuzawa, Y. 1997. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab. Rev. 13:3-13.
6. National Cholesterol Education Program. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2486-2497.
7. International Diabetes Federation. 2005. A new worldwide definition of the metabolic syndrome. http://www.idf.org/home/index.cfm?unode=32EF2063-B966- 468F-928C-A5682A4E3910.
8. Taniguchi, C.M., Emanuelli, B., and Kahn, C.R. 2006. Critical nodes in signaling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7:85-96.
9. Saltiel, A.R., and Kahn, C.R. 2001. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 414:799-806.
10. Kahn, C.R. 2000. Triglycerides and toggling the tummy. Nat. Genet. 25:6-7.
11. Spiegelman, B.M., and Flier, J.S. 2001. Obesity and regulation of energy balance. Cell. 104:531-543.
12. Lowell, B.B. 1999. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 99:239-242.
13. Chawla, A., Saez, E., and Evans, R.M. 2000. Don't know much bile-ology. Cell. 103:1-4.
14. Obici, S., Feng, Z., Arduini, A., Conti, R., and Rossetti, L. 2003. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat. Med. 9:756-761.
15. Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87-91.
16. Zhang, Y., et al. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425-432.
17. Steppan, C.M., et al. 2001. The hormone resistin links obesity to diabetes. Nature. 409:307-312.
18. Yang, Q., et al. 2005. Serum retinal binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 436:356-362.
19. Lazar, M.A. 2006. The humoral side of insulin resistance. Nat. Med. 12:43-44.
20. Kershaw, E.E., and Flier, J.S. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89:2548-2556.
21. Kadowaki, T., and Yamauchi, T. 2005. Adiponectin and adiponectin receptors. Endocr. Rev. 26:439-451.
22. Berg, A.H., and Scherer, P.E. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96:939-949.
23. Okamoto, Y., Kihara, S., Funahashi, T., Matsuzawa, Y., and Libby, P. 2006. Adiponectin: a key adipocytokine in metabolic syndrome. Clin. Sci. (Lond.) 110:267-278.
24. Scherer, P.E., Williams, S., Fogliano, M., Baldini, G., and Lodish, H.F. 1995. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270:26746-26749.
25. Hu, E., Liang, P., and Spiegelman, B.M. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271:10697-10703.
26. Maeda, K., et al. 1996. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 221:286-289.
27. Nakano, Y., Tobe, T., Choi-Miura, N.H., Mazda, T., and Tomita, M. 1996. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. (Tokyo). 120:803-812.
28. Shapiro, L., and Scherer, P.E. 1998. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8:335-338.
29. Yokota, T., et al. 2000. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 96:1723-1732.
30. Crouch, E., Persson, A., Chang, D., and Heuser, J. 1994. Molecular structure of pulmonary surfactant protein D (SP-D). J. Biol. Chem. 269:17311-17319.
31. McCormack, F.X., et al. 1997. The Cys6 intermolecular disulfide bond and the collagen-like region of rat SP-A play critical roles in interactions with alveolar type II cells and surfactant lipids. J. Biol. Chem. 272:27971-27979.
32. Pajvani, U.B., et al. 2003. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem. 278:9073-9085.
33. Waki, H., et al. 2003. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J. Biol. Chem. 278:40352-40363.
34. Hotta, K., et al. 2001. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 50:1126-1133.
35. Arita, Y., et al. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257:79-83.
36. Ryo, M., et al. 2004. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 68:975-981.
37. Yatagai, T., et al. 2003. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism. 52:1274-1278.
38. Yamamoto, Y., Hirose, H., Saito, I., Nishikai, K., and Saruta, T. 2004. Adiponectin, an adipocytederived protein, predicts future insulin-resistance: two-year follow-up study in Japanese population. J. Clin. Endocrinol. Metab. 89:87-90.
39. Lindsay, R.S., et al. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 360:57-58.
40. Daimon, M., et al. 2003. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care. 26:2015-2020.
41. Snehalatha, C., et al. 2003. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care. 26:3226-3229.
42. Spranger, J., et al. 2003. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 361:226-228.
43. Duncan, B.B., et al. 2004. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes. 53:2473-2478.
44. Krakoff, J., et al. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care. 26:1745-1751.
45. Matsushita, K., et al. 2006. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler. Thromb. Vasc. Biol. 26:871-876.
46. Kumada, M., et al. 2003. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 23:85-89.
47. Pischon, T., et al. 2004. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 291:1730-1737.
48. Ouchi, N., et al. 2003. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 42:231-234.
49. Adamczak, M., et al. 2003. Decreased plasma adiponectin concentration in patients with essential hypertension. Am. J. Hypertens. 16:72-75.
50. Combs, T.P., et al. 2003. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 52:268-276.
51. Nishizawa, H., et al. 2002. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 51:2734-2741.
52. Xu, A., et al. 2005. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J. Biol. Chem. 280:18073-18080.
53. Nagasawa, A., et al. 2002. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm. Metab. Res. 34:635-639.
54. Flachs, P., et al. 2006. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. 49:394-397.
55. Nagao, K., et al. 2003. Conjugated linoleic acid enhances plasma adiponectin level and alleviates hyperinsulinemia and hypertension in Zucker diabetic fatty (fa/fa) rats. Biochem. Biophys. Res. Commun. 310:562-566.
56. Pischon, T., et al. 2005. Association between dietary factors and plasma adiponectin concentrations in men. Am. J. Clin. Nutr. 81:780-786.
57. Furukawa, S., et al. 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114:1752-1761. doi:10.1172/JCI200421625.
58. Yamauchi, T., et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:941-946.
59. Berg, A.H., et al. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-953.
60. Fruebis, J., et al. 2001. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98:2005-2010.
61. Yamauchi, T., et al. 2003. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278:2461-2468.
62. Combs, T.P., et al. 2004. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 145:367-383.
63. Kubota, N., et al. 2002. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277:25863-25866.
64. Maeda, N., et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8:731-737.
65. Ma, K., et al. 2002. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J. Biol. Chem. 277:34658-34661.
66. Nawrocki, A.R., et al. 2006. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 281:2654-2660.
67. Yamauchi, T., et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8:1288-1295.
68. Tomas, E., et al. 2002. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. U. S. A. 99:16309-16313.
69. Combs, T.P., et al. 2001. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108:1875-1881. doi:10.1172/JCI200114120.
70. Kissebah, A., et al. 2000. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 97:14478-14483.
71. Mori, Y., et al. 2002. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate loci on 7p and 11p. Diabetes. 51:1247-1255.
72. Vasseur, F., et al. 2002. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocytesecreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum. Mol. Genet. 11:2607-2614.
73. Hara, K., et al. 2002. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 51:536-540.
74. Kondo, H., et al. 2002. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 51:2325-2328.
75. Stumvoll, M., et al. 2002. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes. 51:37-41.
76. Menzaghi, C., et al. 2002. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes. 51:2306-2312.
77. Woo, J.G., et al. 2006. Interactions between non-contiguous haplotypes in the adiponectin gene ACDC are associated with plasma adiponectin. Diabetes. 55:523-529.
78. Tasanen, K., et al. 2000. Collagen XVII is destabilized by a glycine substitution mutation in the cell adhesion domain Col15. J. Biol. Chem. 275:3093-3099.
79. Pajvani, U.B., et al. 2004. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279:12152-12162.
80. Lara-Castro, C., et al. 2006. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 55:249-259.
81. Fisher, F.F., et al. 2005. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 48:1084-1087.
82. Ebinuma, H., et al. 2006. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin. Chim. Acta. doi:10.1016/j.cca.2006.03.014.
83. Hara, K., et al. 2006. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 29:1357-1362.
84. Yamauchi, T., et al. 2003. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 423:762-769.
85. Karpichev, I.V., et al. 2002. Multiple regulatory roles of a novel Saccharomyces cerevisiae protein, encoded by YOL002c, in lipid and phosphate metabolism. J. Biol. Chem. 277:19609-19617.
86. Hug, C., et al. 2004. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U. S. A. 101:10308-10313.
87. Kubota, N., et al. 2006. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem. 281:8748-8755.
88. Mao, X., et al. 2006. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 8:516-523.
89. Tsuchida, A., et al. 2004. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J. Biol. Chem. 279:30817-30822.
90. Civitarese, A.E., et al. 2004. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia. 47:816-820.
91. Debard, C., et al. 2004. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia. 47:917-925.
92. Harald, S., et al. 2004. Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes. 53:2195-2201.
93. Kharroubi, I., et al. 2003. Expression of adiponectin receptors in pancreatic beta cells. Biochem. Biophys. Res. Commun. 312:1118-1122.
94. Bowen, L., et al. 1991. The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism. 40:1025-1030.
95. Nolan, J.J., et al. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331:1188-1193.
96. Saltiel, A.R. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 104:517-529.
97. Mauvais-Jarvis, F., et al. 2000. Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic and knockout mice? Diabetes Metab. 26:433-448.
98. Yki-Jarvinen, H. 2004. Thiazolidinediones. N. Engl. J. Med. 351:1106-1118.
99. Rangwala, S.M., et al. 2004. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 25:331-336.
100. Okuno, A., et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1354-1361.
101. Evans, R.M., et al. 2004. PPARs and the complex journey to obesity. Nat. Med. 10:355-361.
102. Kubota, N., et al. 1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
103. Olefsky, J.M., et al. 2000. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 11:362-368.
104. Yu, J.G., et al. 2002. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 51:2968-2974.
105. Chandran, M., et al. 2003. Adiponectin: more than just another fat cell hormone? Diabetes Care. 26:2442-2450.
106. Iwaki, M., et al. 2003. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 52:1655-1663.
107. Hirose, H., et al. 2002. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 51:314-317.
108. Maeda, N., et al. 2001. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2094-2099.
109. Yamauchi, T., et al. 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276:41245-41254.
110. Furuhashi, M., et al. 2003. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 42:76-81.
111. Koh, K.K., et al. 2005. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 45:1088-1093.
112. Yang, W.S., et al. 2001. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab. 86:3815-3819.
113. Esposito, K., et al. 2003. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 289:1799-1804.
114. Kistorp, C., et al. 2005. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 112:1756-1762.
115. Tentolouris, N., et al. 2004. Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease. Horm. Metab. Res. 36:721-727.
116. Chinetti, G., et al. 2004. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem. Biophys. Res. Commun. 314:151-158.
117. Tsuchida, A., et al. 2005. Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 54:3358-3370.
118. Narasimhan, M.L., et al. 2005. Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol. Cell. 17:171-180.